The National Drug Abuse Treatment Clinical Trials Network

描述(由申请人提供)：响应RFA-DA-10-009，本申请寻求续签国家药物滥用治疗临床试验网络(CTN)的太平洋地区节点，以继续提高成瘾治疗的质量和提供可由社区治疗提供者(CTP)有效实施的成瘾治疗。由Walter Ling医学博士领导的太平洋地区Node正在进行和未来的研究、培训和传播活动将服务于CTN的使命，“以科学为载体，提高全国药物滥用治疗的质量”。该节点将继续通过领导和参与创新概念开发、严格进行研究、高效管理和有效传播CTN产品，为CTN努力做出重大贡献。例如，在最近的供资期间，节点参与方制定了两项议定书，目前牵头制定了CTN0048的议定书--使用丁丙诺啡减少可卡因使用(抑制)。节点人员将继续编写和传播培训材料和手册，供整个国家技术网络使用，规划和主办面向国家技术网络的会议，并通过培训、专题介绍、出版物和基于互联网的方法传播以技术网络为基础的成果。该节点的活动将推进科学，并以与世界各地的其他节点、CTN CTP和其他提供商和研究人员合作的方式，增加经研究证实的治疗的广泛实施。这一更新提议在现有的五个CTP的基础上增加两个CTP，增加地理存在和种族/族裔包容性，并确保获得每一个可能的环境、模式、特殊人口和药物滥用问题。太平洋地区节点打算加快新药和行为疗法的开发和测试，这些药物和行为疗法可以整合在一起，以实现更好的结果。通过增加与提供者团体和研究人员审查潜在疗法的互动，在建立新的协作和涉及更广泛的环境的同时，利用Node的现有合作伙伴关系，将增强创新、研究进度和相关性。太平洋地区节点的更新将通过与NIDA、CTN参与者和其他利益攸关方的协作工作来加强CTN努力。 公共卫生相关性：为了促进使用经研究证实的成瘾治疗方法，太平洋区域节点将继续努力纳入更广泛的CTN研究环境，以便更多地纳入和服务那些没有得到传统CTP全面服务的人群。该节点将继续与整个CTN合作，以确定和解决成瘾挑战、公共卫生需求和研究问题。

DESCRIPTION (provided by applicant): Responding to RFA-DA-10-009, this application seeks renewal of the Pacific Region Node of the National Drug Abuse Treatment Clinical Trials Network (CTN) to continue improving the quality and delivery of addiction treatments that can be implemented efficiently by community-based treatment providers (CTPs). The ongoing and future research, training, and dissemination activities of the Pacific Region Node, led by Walter Ling, M.D., will serve the CTN mission "to improve the quality of drug abuse treatment throughout the country, using science as a vehicle." The Node will continue to contribute significantly to the CTN effort by its leadership and participation in innovative concept development, rigorous conduct of research, efficient management, and effective dissemination of CTN products. In the most recent funding period, for example, Node participants developed two protocols and currently lead protocol development of CTN0048, Cocaine Use Reduction with Buprenorphine (CURB). Node personnel will continue to develop and disseminate training materials and manuals for use across the CTN, to plan and host CTN-oriented conferences, and disseminate CTN-based findings through trainings, presentations, publications, and Internet-based methods. The Node's activities will advance the science and increase broad implementation of research-proven treatments in a collaborative manner with other nodes, CTN CTPs, and other providers and researchers worldwide. This renewal proposes adding two CTPs to the existing five, increasing geographic presence and racial/ethnic inclusion as well as ensuring access to every possible setting, modality, special population, and drug abuse problem. The Pacific Region Node intends to accelerate development and testing of new medications and behavioral therapies that can be integrated to achieve better outcomes. Innovation, research pacing, and relevance will be enhanced by increasing interaction with provider groups and with researchers examining potential therapies, exploiting the Node's existing partnerships while building new collaborations and involving more broad-based settings. Renewal of the Pacific Region Node will strengthen CTN efforts through collaborative work with NIDA, CTN participants, and other stakeholders. PUBLIC HEALTH RELEVANCE: To promote use of research-proven addiction treatments, the Pacific Region Node will continue its work to incorporate more broad-based settings for CTN research, resulting in greater inclusion of and service to populations that are not comprehensively served by traditional CTPs. The Node will continue collaboration with the overall CTN to identify and address addiction challenges, public health needs, and research issues.